Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 118

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H1 2018

Summary

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) pipeline Target constitutes close to 37 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H1 2018, outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 3, 4, 15 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 8 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Oncology, Metabolic Disorders, Cardiovascular, Respiratory, Ophthalmology, Gastrointestinal, Genito Urinary System And Sex Hormones, Toxicology, Genetic Disorders, Infectious Disease and Musculoskeletal Disorders which include indications Inflammation, Multiple Sclerosis, Diabetic Nephropathy, Chronic Obstructive Pulmonary Disease (COPD), Friedreich Ataxia, Psoriasis, Type 2 Diabetes, Amyotrophic Lateral Sclerosis, Chronic Kidney Disease (Chronic Renal Failure), Mitochondrial Diseases, Parkinson's Disease, Pulmonary Arterial Hypertension, Retinal Degeneration, Systemic Sclerosis (Scleroderma), Type 1 Diabetes (Juvenile Diabetes), Age Related Macular Degeneration, AIDS Associated Dementia, Alport Syndrome, Alzheimer's Disease, Aspiration Pneumonitis, Asthma, Atherosclerosis, Autism, Brain Ischemia, Breast Cancer, Cardiomyopathy, Cardiovascular Disease, Cerebral Vasospasm, Chagas Disease (American Trypanosomiasis), Diabetic Complications, Encephalomyelitis, Focal Segmental Glomerulosclerosis (FSGS), Glomerulonephritis, Huntington Disease, Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Hypertension, Ischemia Reperfusion Injury, Ischemic Stroke, Medulloblastoma, Metastatic Breast Cancer, Metastatic Melanoma, Neuroblastoma, Neurodegenerative Diseases, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Osteoarthritis, Osteoporosis, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Polycystic Kidney Disease, Post-Myocardial Infarction, Primary Progressive Multiple Sclerosis (PPMS), Prostate Cancer, Proteinuria, Pulmonary Hypertension, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Radiodermatitis, Relapsing Remitting Multiple Sclerosis (RRMS), Retinopathy, Subarachnoid Hemorrhage and Ulcerative Colitis.

Furthermore, this report also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)

- The report reviews Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics and enlists all their major and minor projects

- The report assesses Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Overview
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Companies Involved in Therapeutics Development
Arbor Pharmaceuticals LLC
Bayer AG
BioApex sro
Biogen Inc
C4X Discovery Holdings PLC
Catabasis Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Evgen Pharma Plc
Ixchel Pharma LLC
Jiangsu Hengrui Medicine Co Ltd
Mochida Pharmaceutical Co Ltd
Reata Pharmaceuticals Inc
Rigel Pharmaceuticals Inc
vTv Therapeutics Inc
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Drug Profiles
(alpha lipoic acid + losartan potassium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BA-1521 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bardoxolone methyl - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAT-4001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DH-404 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dimethyl fumarate DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IXC-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LGM-2605 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LH-503 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LH-526 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MG-132 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MIND-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
monosodium luminol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nifurtimox - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omaveloxolone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-970 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RS-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RTI-79 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFX-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFX-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFX-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Nrf2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Nrf2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target NRF2 and BACH1 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules 2 to Activate Nrf2 for Oncology and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate NFE2L2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate NRF-2 for COPD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Nrf2 for Oncology and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target GSK3B and Nrf2 for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUL-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TBE-31 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tepilamide fumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TFM-735 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VCB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VCB-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VEDA-1209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Dormant Products
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Discontinued Products
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Product Development Milestones
Featured News & Press Releases
Jun 04, 2018: Reata Announces That Kyowa Hakko Kirin Initiated AYAME, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of Diabetic Kidney Disease
May 31, 2018: Kyowa Hakko Kirin Initiated Phase 3 Clinical Study of Bardoxolone Methyl (RTA 402) for Diabetic Kidney Disease
May 31, 2018: Reata Announces Orphan Drug Designation From the European Commission for Bardoxolone Methyl for the Treatment of Alport Syndrome
May 25, 2018: Bardoxolone Methyl Improved Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease and IgA Nephropathy in the Ongoing Phase 2 Phoenix Study
May 02, 2018: Evgen Pharma: Grant of further European patent
Apr 24, 2018: Evgen Pharma Announces Presentation at World Orphan Drug Congress USA
Apr 24, 2018: Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone in the Treatment of Friedreich's Ataxia and Other Severe Neurological Diseases
Apr 11, 2018: Reata Provides Update on the Phase 2 Portion of the CARDINAL Study of Bardoxolone Methyl in Patients with Alport Syndrome
Mar 29, 2018: Reata Announces That Kyowa Hakko Kirin Received SAKIGAKE Priority Review Designation for Bardoxolone Methyl in Japan
Mar 28, 2018: Bardoxolone Methyl (RTA 402) Designated for the Treatment of Diabetic Kidney Disease under the Priority Review and Designation System by the Ministry of Health, Labour and Welfare
Mar 22, 2018: Reata Announces Positive Top-Line Data for Treatment of PH-ILD With Bardoxolone Methyl From the Phase 2 Lariat Trial
Mar 06, 2018: V ClinBio Partners with Camargo for Strategic 505(b)(2) Development of Multiple Sclerosis Drug Candidate CLX-106
Mar 05, 2018: Evgen Pharma: Update on novel sulforaphane analogues
Mar 01, 2018: Reata Announces Top-Line Data from the Dose-Escalation Cohorts of the Phase 2 Motor Study of Omaveloxolone in Patients With Mitochondrial Myopathies
Feb 27, 2018: Reata Provides Program Update on Phase 2 Rare Renal Clinical Trials
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1)
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Arbor Pharmaceuticals LLC, H1 2018
Pipeline by Bayer AG, H1 2018
Pipeline by BioApex sro, H1 2018
Pipeline by Biogen Inc, H1 2018
Pipeline by C4X Discovery Holdings PLC, H1 2018
Pipeline by Catabasis Pharmaceuticals Inc, H1 2018
Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Pipeline by Evgen Pharma Plc, H1 2018
Pipeline by Ixchel Pharma LLC, H1 2018
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Pipeline by Mochida Pharmaceutical Co Ltd, H1 2018
Pipeline by Reata Pharmaceuticals Inc, H1 2018
Pipeline by Rigel Pharmaceuticals Inc, H1 2018
Pipeline by vTv Therapeutics Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Dormant Products, H1 2018 (Contd..2), H1 2018
Discontinued Products, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global HPV Therapeutic Vaccines Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 18-Sep-2018        Price: US 3480 Onwards        Pages: 109
    Human papilloma virus (HPV) vaccines are used to protect against HPV infections. Human Papillomaviruses (HPV) are members of papillomaviridae family a group of more than 150 related viruses. These are specifically known as papillomaviruses because of some of its types give rise to a wart or papilloma which are benign growths. Some of them are also associated with certain cancers and known as carcinogenic HPVs. Scope of the Report: This report focuses on the ......
  • Global Human Chorionic Gonadotropin (HCG) Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 18-Sep-2018        Price: US 3480 Onwards        Pages: 117
    Human chorionic gonadotropin (HCG) is a female hormone produced by the placenta after implantation of the egg, which is why it can be detected in a few pregnancy tests. In addition, it can be extracted from the urine of pregnant women or produced from cultures of genetically modified cells using recombinant DNA technology. Scope of the Report: This report focuses on the Human Chorionic Gonadotropin (HCG) in global market, especially in North America, Europe and Asi......
  • Global Imatinib Drug Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 18-Sep-2018        Price: US 3480 Onwards        Pages: 120
    Imatinib is a chemotherapy drug that acts by reducing or preventing the progression of cancer cells. This drug is used for the treatment of certain cancers such as chronic myeloid leukemia, acute lymphoblastic leukemia, gastrointestinal tumors, certain skin tumors (dermatofibrosarcoma protuberans), and myelodysplastic/myeloproliferative diseases. Scope of the Report: This report focuses on the Imatinib Drug in global market, especially in North America, Europe and A......
  • 2018-2023 Global Novel Drug Delivery Systems Consumption Market Report
    Published: 18-Sep-2018        Price: US 4660 Onwards        Pages: 184
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Novel Drug Delivery Systems market for 2018-2023. Novel Drug delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. NDDS is a system for delivery of drug other than conventional drug delivery system. NDDS is a......
  • 2018-2023 Global Non-Radioactive Nucleic Acid Labeling Product Consumption Market Report
    Published: 18-Sep-2018        Price: US 4660 Onwards        Pages: 135
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Non-Radioactive Nucleic Acid Labeling Product market for 2018-2023. In recent years, non-radioactive nucleic acid labeling and detection methodologies have become available in response to a desire by researchers and their institutions to move away from the use of radioisotopes. Advancements made in the areas of chemiluminescence and fluorescence have allowe......
  • 2018-2023 Global mRNA Vaccines & Therapeutics Consumption Market Report
    Published: 18-Sep-2018        Price: US 4660 Onwards        Pages: 136
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global mRNA Vaccines & Therapeutics market for 2018-2023. mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensu......
  • 2018-2023 Global Compounding Pharmacy Market Report (Status and Outlook)
    Published: 18-Sep-2018        Price: US 4660 Onwards        Pages: 130
    In this report, LP Information studies the present scenario (with the base year being 2017) and the growth prospects of global Compounding Pharmacy market for 2018-2023. The traditional role of compounding pharmacies is to make drugs prescribed by doctors for specific patients with needs that can't be met by commercially available drugs. For example: A young child may need a small, liquid dose of a drug made only in adult-dosage tablets. A person may be allergic to o......
  • 2018-2023 Global Eucalyptus Oil Consumption Market Report
    Published: 18-Sep-2018        Price: US 4660 Onwards        Pages: 161
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Eucalyptus Oil market for 2018-2023. Eucalyptus oil is the generic name for distilled oil from the leaf of Eucalyptus, a genus of the plant family Myrtaceae native to Australia and cultivated worldwide. Eucalyptus oil is one of the most common and widely used essential oils and has a good health care effect. It is colorless or slightly yellow liquid.......
  • 2018-2023 Global Self-Monitoring Blood Glucose (SMBG) Devices Consumption Market Report
    Published: 18-Sep-2018        Price: US 4660 Onwards        Pages: 138
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Self-Monitoring Blood Glucose (SMBG) Devices market for 2018-2023. Self-monitoring of blood glucose (SMBG) is an important component of modern therapy for diabetes mellitus. SMBG has been recommended for people with diabetes and their health care professionals in order to achieve a specific level of glycemic control and to prevent hypoglycemia. The goal of ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs